Santé & Sciences de la vie

Etude

Measuring the return from pharmaceutical innovation

14th edition

Our latest analysis shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

Our latest analysis shows companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

Point de vue

Access to Medicine: Reach more patients through a deeper understanding of access issues